Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab vs Cisplatin with IMRT in Stage II-III NPC
NCT03837808Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2019
- Primary completion
- Feb 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nimotuzumab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03837808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03837808.